Merchavia Holdings And Investments Ltd · TASE:MRHL
Merchavia Holdings And Investments — Investor Presentation (June 2021)
25 slides from Merchavia Holdings And Investments's investor presentation, June 2021
Slide 1: Life Science. Massive Opportunity. Massive Impact
LIFE SCIENCE . MASSIVE OPPORTUNITY . MASSIVE IMPACT 1
Slide 2: Disclaimer
Disclaimer: This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any shares or other securities of Merchavia Holdings and Investments Ltd. (th
Slide 3: Life Science - Massive Opportunity. Massive Impact.
LIFE SCIENCE - MASSIVE OPPORTUNITY. MASSIVE IMPACT. The size of the medical devices market in 2020 reached $456 Billion $603 Billion The medical devices market is expected to grow at a CAGR of 6.1% from 2021 and reach The global Digital Health Market in 2019 was approximately $84 Billion The market
Slide 4: Age advance is the most important risk factor for cancer
AGE ADVANCE IS THE MOST IMPORTANT RISK FACTOR FOR CANCER 4
Slide 5: The incidence rate for cancer overall climbs steadily as age increases
The incidence rate for cancer overall climbs steadily as age increases from fewer than to about 350 cases to more than 1,000 25 cases per 100,000 per 100,000 people per 100,000 people people in age groups among those in age groups under age 20 aged 45–49 60 years + 5 Sources: https://www.cancer.gov/
Slide 6: The chances of cancer and coronary heart disease are 40 times higher
The chances of cancer and coronary heart disease at age 60 is 40 times higher than at age 20 6 Sources: https://www.cancer.gov/about-cancer/causes-prevention/risk/age https://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_449846.pdf
Slide 7: Digital revolution in medicine
Digital revolution in medicine Economic burden on global Early detection of serious The solution: medical systems and chronic diseases is the Accelerated necessitates change key to coping technological innovation for the medical world 7
Slide 8: Identifying the right opportunities at the right time leads to success
Identifying the right opportunities at the right time leads to success Identifying companies Huge business potential Significant value increase with low technological risk 8
Slide 9: Strong management team
Strong management team Strong management team with a combined background in the fields of capital markets and the life sciences. Eli Arad Rani Lifshitz Dr. Eran Schenker Ilan Goldstein CEO Chairman of the Board Medical Director | IL President Has vast experience with Israeli Attorney and economist w
Slide 10: Members of the Scientific Advisory Committee
Members of the Scientific Advisory Committee Expertise and international connections from Israel and the US Dr. Arnon Chait USA Founder and CEO of Cleveland Diagnostics, Inc. Has over 25 years of experience in NASA. Founded and led biomed companies, research companies and companies engaged in optica
Slide 11: Merchavia's strategy - guerrilla investments
Merchavia's strategy - guerrilla investments • Investments that enable involvement and influence from an early stage. • Ability to maintain our share in continuing investments. • Transparent and declared dividend policy. • A “lean and mean” team and lineup. 11
Slide 12: Identifying the right opportunities at the right time leads to success
Identifying the right opportunities at the right time leads to success In 6 years of investment activity in 10 companies out of 10 value increase in 12
Slide 13: Identifying the right opportunities at the right time leads to success
Identifying the right opportunities at the right time leads to success 4 Portfolio companies First exit RMDY merged Raised investments in the Last round valuation with OPRX, a company past year in a total combined in 4 companies at traded on Nasdaq. amount of $28 million.* $220 million in total. * 1
Slide 14: An increase of 100% per year
An increase of 100% per year 14
Slide 15: CDx: Detecting cancer early (IsoPSA)
MILESTONE The FDA has granted IsoPSA a "Breakthrough Device Designation". MULTI BILLION DOLLAR MARKET additional tests for breast cancer, lung cancer and other disease diagnosis CLINICAL STAGE ●Detecting ISOPSA first test in the market, FDA submission completed, approval decision Detecting cancer ea
Slide 16: EFA: RevDx hand-held CBC device
MILESTONE CBC is the most requested test worldwide and the physician’s “best practice”. MULTI BILLION DOLLAR MARKET Helps diagnose infectious diseases, hematological malignancies and immune system deficiencies. CLINICAL STAGE Clinical pilot trial with Maccabi. EFA develops RevDx. The First Affordabl
Slide 17: VEOLI: medical cannabis delivery
MILESTONE Since there is no heating in the process, there is no change in the properties of the cannabis and no production of byproducts that usually occur during heating or burning. MULTI BILLION DOLLAR MARKET? According to marketwatch, the medical cannabis market is expected to grow up to $39 bill
Slide 18: CardiacSense: wearable sensor technology
MILESTONE Cardiacsense have signed distribution agreements for more than $100M for the next 4 years MULTI BILLION DOLLAR MARKET Several other near-term applications are in development, including monitoring of other arrhythmias and vital signs such as blood pressure, respiratory rate, and oxygen satu
Slide 19: TrainPain: digital therapeutic for chronic pain
MILESTONE TrainPain approach is to train the brain to get better - on its own - at regulating nerve activity. MULTI BILLION DOLLAR MARKET According to marketwatch, the chronic pain treatment market is expected to grow to about $83 billion by 2024. CLINICAL STAGE TrainPain finalized first clinical tr
Slide 20: Aura Smart Air: air quality management
MILESTONE Aura detects indoor and outdoor air quality based on real-time monitoring through an array of smart sensors. MULTI BILLION DOLLAR MARKET “Indoor air is 5 TIMES more polluted than outdoor air” World Health Organization SALES Marketing and sales, revenues initiated at Q4 2020. 2020 revenues
Slide 21: Nervio: AI-driven neuromonitoring
MILESTONE Neuromonitoring is the only tool to prevent nerve injury during surgery. Spine, neck & other surgeries involve high risk of nerve injury. Neuromonitoring is a real-time, complex, error-prone process which is highly dependent on the user's experience and expertise. MULTI BILLION DOLLAR MARK
Slide 22: Ocon Medical: women's health products
MILESTONE The first product, Ballerine, is a long term (5 years in current markets) copper- based hormone-free intrauterine contraceptive. It is currently sold in 30 countries. To date, over ~100,000 women have used Ballerine. MULTI BILLION DOLLAR MARKET The next product based on the same platform i
Slide 23: Upcoming Milestones over the next 18 Months
Upcoming Milestones over the next 18 Months Completion of clinical Completion of PHASE IIa Expanding sales and FDA approval FDA clearance for AF detection. pilot trial. clinical trial in The SEAD. marketing 2021. for ISOPSA test. First batch of 3,000 watches Series A round. Series A round. In the pr
Slide 24: We have all the necessary components for investing properly in life sciences
We have all the necessary components for investing properly in life sciences Investments with the right The right team + global Proven successes timing, after proving strategic connections technological feasibility 24
Slide 25: Thank you!
25 Thank you! J IXNN MERCHAVIA Invest in Life
Merchavia Holdings and Investments — Investor Presentation (June 2021) on 6ix